A5027214799- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Integrated Circuits and Semiconductor Failure Analysis
- Lung Cancer Treatments and Mutations
- Nail Diseases and Treatments
- Acute Lymphoblastic Leukemia research
- Circadian rhythm and melatonin
- Galectins and Cancer Biology
- Light effects on plants
- Immunodeficiency and Autoimmune Disorders
- Vascular Tumors and Angiosarcomas
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Cancer Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Nanowire Synthesis and Applications
Massachusetts General Hospital
2015-2025
Harvard University
2013-2025
Martha's Vineyard Hospital
2025
European School of Oncology
2019
John Wiley & Sons (United States)
2019
Dana-Farber Cancer Institute
2018
Harvard University Press
2018
University of Illinois Urbana-Champaign
1999-2004
University of California, Irvine Medical Center
1986
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic lymphoma, anaplastic large cell lymphoma kinase–positive, kinase–negative, and enteropathy-associated lymphoma. This discussion section focuses on diagnosis treatment PTCLs as outlined in NCCN Guidelines T-Cell Lymphomas.
The outcome of patients with systemic diffuse large B-cell lymphoma (DLBCL) had improved over the past decade addition monoclonal antibody therapy. Unfortunately, approximately 5% these still developed a secondary central nervous system (CNS) recurrence followed invariably by rapid death. This rate is substantially increased in certain high-risk features. Although prophylaxis against CNS either intrathecal or intravenous methotrexate commonly used for such patients, to authors' knowledge,...
Despite a central circadian role in Drosophila for the transcriptional regulator Timeless ( dTim ), relevance of mammalian mTim ) remains equivocal. Conditional knockdown protein expression rat suprachiasmatic nucleus (SCN) disrupted SCN neuronal activity rhythms, and altered levels known core clock elements. Full-length (mTIM-fl) exhibited 24-hour oscillation, where as truncated isoform (mTIM-s) was constitutively expressed. mTIM-fl associated with Period proteins (mPERs) oscillating cells....
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) a rare erythrodermic leukemic CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy often necessary for treatment advanced-stage disease. Systemic options have evolved in recent years approval novel agents such as romidepsin, brentuximab vedotin, mogamulizumab. These...
The optimal therapy for primary mediastinal B-cell lymphoma is a subject of ongoing debate, with no accepted standard care. We performed retrospective analysis 63 patients in the modern era treated rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), or without radiation. Median age was 37 years (range 20-82). Eighty percent had limited stage disease 71% were bulky. By age-adjusted International Prognostic Index (IPI), 15% low-risk, 52% low-intermediate, 27%...
Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell predominantly extranodal most these nasal type, often localized to the upper aerodigestive tract. Because (ENKL) malignancies, randomized trials comparing different regimens have not been conducted date standard therapy has yet established for patients. These NCCN Guidelines Insights discuss recommendations diagnosis management patients with ENKL as outlined in T-Cell Lymphomas.
HIV‐positive patients have been excluded from clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapies. Herein, the authors report on 2 with HIV/AIDS–associated, chemotherapy‐refractory, aggressive B‐cell lymphomas who were treated successfully anti‐CD19 CAR product axicabtagene ciloleucel.
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of associated with an aggressive clinical course and worse prognosis. HSTCL develops in the setting chronic immune suppression or dysregulation up to 20% cases most often characterized by spleen, liver, bone marrow involvement. Diagnosis management pose significant challenges given rarity disease along absence lymphadenopathy poor outcome conventional chemotherapy regimens. These Guidelines Insights focus on diagnosis treatment as...
Abstract Background Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data patients with central nervous system (CNS) involvement are limited. Methods We retrospectively report on CNS-specific toxicities, management, and CNS response of 45 consecutive CAR transfusions active lymphoma at the Massachusetts General Hospital over 5-year period. Results Our cohort includes 17 primary (PCNSL; 1 patient...
Background: Venetoclax-obinutuzumab induces durable undetectable MRD (median time to ≥10-4 of 21 mo) in CLL (Al-Sawaf JCO, 2021) and zanubrutinib is a second-generation BTKi with favorable safety profile (Brown NEJM 2023). BOVen appeared well-tolerated achieved frequent uMRD (Soumerai Lancet Haem 2021), but longer follow-up was needed evaluate the MRD-driven treatment strategy. Herein, we present initial report on long-term CLL. Methods: In this multicenter phase 2 trial (NCT03824483),...
BACKGROUND High‐dose thiotepa, busulfan, and cyclophosphamide (TBC) with autologous stem cell transplantation (ASCT) has been used in patients central nervous system (CNS) involvement by non‐Hodgkin lymphoma (NHL). Despite limited penetration into the CNS, rituximab is active primary CNS NHL. Therefore, high‐dose was combined TBC for ASCT METHODS A single‐arm phase 2 trial using cytarabine mobilization followed (R‐TBC) conducted. Doses of at 1000 mg/m were given on days 1 8 −9 −2 TBC. The...
Diffuse large B-cell lymphoma is an aggressive non-Hodgkin's without a standard therapy for patients who relapse after or are not eligible salvage autologous stem cell transplantation. In vitro analysis of lines has shown that everolimus can inhibit cycle progression in and inhibitors the mammalian target rapamycin have already demonstrated single-agent activity relapsed lymphomas including diffuse lymphoma, validating as viable therapeutic target. We performed open label phase II study...
Background: TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes standard chemoimmunotherapy. Dual BTK and BCL2-inhibition or without anti-CD20 monoclonal antibody therapy has shown promising activity in MCL. We conducted a multi-center phase 2 study of zanubrutinib, obinutuzumab, venetoclax (BOVen) untreated MCL patients TP53 mutation. Patients initially received zanubrutinib 160mg twice daily obinutuzumab. Obinutuzumab 1000mg was given on cycle 1 day 1, 8, 15...
Abstract Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation. Results: Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma (ENKTCL), T-prolymphocytic leukemia (T-PLL),...
Chronic lymphocytic leukemia (CLL), the most common worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies. Whether elicited antibodies are functional and/or accompanied by T-cell responses unknown. This prospective cohort study included who received SARS-CoV-2 and PCV13 vaccines (not concurrently). The primary adults off therapy....